Antitrust Radar

Competition issue dossier

Health care intermediaries

How do insurer structure, PBM contracting, rebate, formulary, network, and organizational relationships affect competition and patient access across separately measured health-care systems?

The program connects the 2024 KFF state individual-insurance concentration cross-section to separately bounded public PBM facts, named official records, source limits, and evidence requests without treating payer and prescription-intermediary systems as one market.

Inspect evidence Compare Atlas JSON CSV
Bounded markets2
Evidence routes26
Official records4
Source custody6
Updated through2026-07-20
Interpretation boundaryIssue program, not market definition

KFF state rows cover the ACA-regulated individual market, while published PBM top-three and top-six aggregates cover prescription processing and do not support an HHI calculation or a finding about any individual firm. The two systems are not combined.

Use standard

01 / Bounded market screens

Keep each measure inside its declared universe.

2 market profiles remain separate inside this issue program. Census rows are navigation context, not substitutes.

Health insurance

U.S. ACA individual health insurance

United States / separately reported state and District of Columbia markets / 2024

HHI3,650CR4Not reportedTop shareNot reportedEvidenceEstimated Publichigh confidence
Health care

U.S. pharmacy benefit management

United States / 2023

HHIWithheldCR4Not reportedTop shareNot reportedEvidenceIncompletehigh confidence
Census navigation context2 declared six-digit screens
NAICS 524114Direct health and medical insurance carriersHHI 649.3 / CR4 44.2% / 747 firmsNAICS 524292Pharmacy benefit management and other third party administration of insurance and pension fundsHHI 1,633.5 / CR4 77.3% / 2,480 firms

02 / Research program

Turn the issue frame into testable evidence requests.

Program questions are editorial research designs. Canonical dossiers appear only where the observatory has a definition-stable latest-to-prior signal.

Program questions

  1. 01

    Which comparable state insurer enrollment, claims, prescription, rebate, and network records can establish firm-level structure under stable ownership identifiers?

  2. 02

    How do plan entry, insurer structure, contracting, formulary, and network practices differ across payer, pharmacy, patient, and geographic segments?

  3. 03

    Which ownership and control relationships are supported by exact filings rather than name similarity or market context?

Observed change

Canonical signal questions

0
No canonical change question yet.

The current evidence does not contain a definition-stable latest-to-prior signal for this market. The gap remains explicit.

Open agenda

03 / Participants and attribution

Separate source labels from operator evidence.

Participant shares apply only to their source, year, and market. Operator links rely on separate official attribution records and do not establish a complete ownership graph.

Measured rows

Source-labeled participants

0
No firm-level share table.

The current public evidence does not support participant rows for this issue market.

Separate evidence

Official operator attributions

0
No encoded operator attribution.

Market context alone is not enough to assert an operator, owner, or corporate family.

04 / Official record

Read chronology and named organizations as separate evidence.

4 dated records and 9 exact organization labels; no liability or causal inference is added.

Federal Trade Commission / Remedy

FTC announces proposed consent agreement with Caremark

The FTC announced a proposed consent agreement with Caremark and Zinc Health Services addressing formulary design, point-of-sale rebates, fee structures, plan-sponsor transparency, community-pharmacy reimbursement, and access to pharmacy hub services.Open record

Federal Trade Commission / Remedy

FTC announces proposed consent agreement with Express Scripts

The FTC announced a proposed consent agreement with Express Scripts and affiliated entities addressing formulary design, patient cost sharing, manufacturer compensation, plan-sponsor transparency, community-pharmacy reimbursement, and related business practices.Open record

Federal Trade Commission / Litigation

FTC files administrative complaint against the three largest PBMs

The FTC brought an administrative action alleging anticompetitive and unfair rebating and formulary practices involving Caremark, Express Scripts, OptumRx, and affiliated GPOs.Open record

Federal Trade Commission / Monitoring

FTC releases interim staff report on prescription drug middlemen

The FTC published interim findings on PBM concentration and vertical integration, including aggregate shares for the largest PBMs.Open record
Exact labels

Named organizations

9

Competition issues are editorial navigation programs assembled from exact public-record links. An issue grouping is not a legal product or geographic market, does not make unlike concentration measures comparable, and does not establish ownership, control, liability, competitive harm, or causality.